The use of a single von Willebrand factor‐containing, plasma‐derived FVIII product in hemophilia A immune tolerance induction: the US experience
Margaret Kurth(Children’s Minnesota - St. Paul Hospital), Louis M. Aledort(Icahn School of Medicine at Mount Sinai), John Puetz(Cardinal Glennon Children’s Medical Center), Charles L. Sexauer(OU Health), Doris Quon(Orthopaedic Hospital), Peter A. Kouides(Unity Health System), Marilyn J. Manco‐Johnson(University of Colorado Anschutz Medical Campus), Jonathan A. Bernstein(Bernstein Clinical Research Center), Brian M. Wicklund(Children's Mercy Hospital), N. RODRIGUEZ(Texas Medical Center), Ellis J. Neufeld(St. Jude Children's Research Hospital), J. Sanders(Cook Children's Medical Center), Ralph A. Gruppo(Cincinnati Children's Hospital Medical Center)
Cited by 46
Related Papers
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.4k
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
|Allergy|2021|1.2k
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Definitions in Hemophilia
|Thrombosis and Haemostasis|2001|772